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Background: Switching to cyclosporin A may result in a reversion of tacrolimus-induced
diabetes mellitus. However, mechanisms underlying such a reversion are still unknown.
Methods: Obese Zucker rats were used as a model for tacrolimus-induced diabetes melli-
tus. A cohort of 44 obese Zucker rats received tacrolimus for 11 days (0.3mg/kg/day) until
diabetes development; then, (a) 22 rats were euthanized at day 12 and were used as a ref-
erence group (tacrolimus-day 12), and (b) 22 rats on tacrolimus were shifted to cyclosporin
(2.5mg/kg/day) for 5 days (tacrolimus-cyclosporin). An additional cohort of 22 obese Zucker
rats received the vehicle for 17 days and was used as a control group. All animals underwent
an intraperitoneal glucose tolerance test at the end of the study.
Results: -Cell proliferation, apoptosis and Ins2 gene expression were evaluated. Compared
to rats in tacrolimus-day 12 group, those in tacrolimus-cyclosporin group showed a sig-
niﬁcant improvement in blood glucose levels in all assessment points in intraperitoneal
glucose tolerance test. Diabetes decreased from 100% in tacrolimus-day-12 group to 50% intacrolimus-cyclosporin group. Compared to tacrolimus-day-12 group, rats in tacrolimus-
cyclosporin group showed an increased -cell proliferation, but such an increase was
lower than in rats receiving the vehicle. Ins2 gene expressions in rats receiving tacrolimus-
cyclosporin and rats receiving the vehicle were comparable.
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Conclusion: An early switch from tacrolimus to cyclosporin in tacrolimus-induced diabetes
mellitus resulted in an increased -cell proliferation and reversion of diabetes in 50% of
cases.
© 2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española de
Nefrología. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Cambios en la homeostasis de la glucosa y la proliferación de la célula
beta pancreática tras el cambio a ciclosporina en la diabetes inducida
por tacrolimus
Palabras clave:
Diabetes postrasplante
Tacrolimus
Ciclosporina-A
r e s u m e n
Antecedentes: El cambio a ciclosporina A podría revertir la diabetes inducida por tacrolimus.
Sin embargo, los mecanismos de esta reversibilidad se desconocen.
Métodos: Usamos como modelo de diabetes inducida por tacrolimus las ratas Zucker obe-
sas. Un grupo de 44 ratas Zucker obesas fue tratado con tacrolimus durante 11días
(0,3mg/kg/día) hasta que desarrollaron diabetes; posteriormente, a) 22 fueron sacriﬁcadas
a día 12 como grupo referencia (tacrolimus-d12), y b) en otras 22 el tacrolimus fue reem-
plazado por ciclosporina (2,5mg/kg/día) durante 5días (tacrolimus-ciclosporina). Veintidós
ratas Zucker obesas recibieron vehículo durante 17días (grupo control). A todos los animales
se les realizó una sobrecarga intraperitoneal de glucosa al ﬁnal del experimento.
Resultados: Se analizó la proliferación de la célula , la apoptosis y la expresión del gen Ins2.
En el grupo tacrolimus-ciclosporina, los niveles de glucemia mejoraron signiﬁcativamente
en cada punto del test intraperitoneal de glucosa comparados con el grupo tacrolimus-d12.
Ladiabetes se redujodel 100%en los tacrolimus-d12hasta el 50%en tacrolimus-ciclosporina.
La proliferación de las células  en tacrolimus-ciclosporina se incrementó en comparación
con tacrolimus-d12, pero fue menor que en los tratados con vehículo. La expresión génica
de Ins2 en tacrolimus-ciclosporina fue comparable a los tratados con el vehículo.
Conclusión: El cambio temprano de tacrolimus por ciclosporina en la diabetes inducida por
tacrolimus incrementa la proliferación de la célula  y revierte la diabetes en un 50% de los
casos.
© 2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española
de Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND
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yclosporine-A (CsA) and tacrolimus (TAC), which are
alcineurin inhibitors (CNI), play a major part in immunosup-
ression after kidney transplantation. TAC is being the most
idely used1 as it offers advantages over CsA in terms of better
raft function and lower rates of acute rejection,1,2 although
t is associated with a higher incidence of post-transplant
iabetes mellitus (PTDM).3 The incidence of PTDM ranges
etween 15 and 25%4–6 and is associated with higher rates
f cardiovascular disease and increased healthcare costs.3,7,8
ence, the study of PTDM induced by TAC is relevant to estab-
ish early preventive and therapeutic strategies that reduce
hese consequences for said population.
According to current guidelines,3,9 PTDM is considered a
ait accompli, and its treatment follows the therapeutic rules
f type 2 diabetes: oral anti-diabetics and/or insulin.9 How-
ver, rarely is action taken upon the compound which most
requently causes PTDM, TAC, that is even though CsA has
lower diabetogenic effect than the former.3,8,9 The change
romTAC toCsA for PTDMreversionhas rarely been suggested.(http://creativecommons.org/licenses/by-nc-nd/4.0/).
In a retrospective study of 34 PTDM cases, Ghisdal et al.
showed remission rates of 42% one year after the change
from TAC to CsA, compared to 0% in the control group, which
remained with TAC.10 Nevertheless, to the best of our knowl-
edge, no study has been carried out with animal models to
establish the mechanisms due to which a change from TAC
to CsA could be a therapeutic alternative in PTDM treat-
ment.
Our group has previously researched the effect of CNI
on homeostasis of glucose and on  cells, both in animals
with and without insulin resistance.11 In this model, the CNI
only induced diabetes in insulin-resistant animals, and TAC
induced more diabetes than CsA (100% vs 40%). Addition-
ally, animals with CsA presented less severe alterations in the
homeostasis of glucose, according to both intraperitoneal glu-
cose tolerance tests as well as blood sugar levels while fasting.
These facts could be explained by a lower reduction of  cell
proliferation and of the expression of the insulin gene with
CsA thanwithTAC.11 With said data, the objective of this study
is to research whether a change from TAC to CsA in insulin-
resistant animalswith diabetes induced by TAC could improve
the homeostasis of glucose, through the induction of changes
015;35(3):264–272
Fig. 1 – Time schedule for the experiment. The animals
were treated with tacrolimus (0.3mg/kg/day) for 11 days,
and they were randomly assigned to one of the following
groups: (a) TAC-d12 (n=22), sacriﬁced on day 12,
or (b) TAC-CSA (n=22), tacrolimus was replaced with CsA
(2.5mg/kg/day) for 5 days. The un-treated control (PBS,
n=23) received PBS for 11 days and was sacriﬁced on day266 nefrolog ia. 2
to the rates of proliferation and apoptosis of  cell and the
expression of the insulin gene.
Material and methods
Animals
In a prior study, we researched the effect of CNI on homeo-
stasis of glucose, in animals both resistant and sensitive to
insulin, i.e. obese (OZR) and thin Zucker rats (TZR).11 OZR
have a homozygous mutation in the leptin receptor (fa/fa),12,13
which results in hyperphagia, obesity, hyperlipidemia, and
severe insulin resistance.14,15 OZR, in normal conditions, are
able to maintain euglycaemia due to a high proliferation of
 cells and due to hypersecretion of insulin.16 It is curious
that the CNI only induces diabetes when they are adminis-
tered to insulin-resistant animals, i.e. OZR, and not to TZR.11
With said data, for this study, we only performed the study on
OZR.
We used animals of between four to six weeks of age, with
a weight of 200±50g (Charles-River, France). They were con-
ﬁned to adequate cages, at 22 ◦C, with a light-darkness cycle of
12h, and fedwithwater and food inpellet ad libitum. The ethics
committee of the Hospital Universitario de Canarias approved
the experiment.
Experimental design
Based on a prior study by our group,11 we induced diabetes
with TAC in obese animals, and then we replaced TAC with
CsA. To do this, we treated a group of OZR (n=44) with TAC
for 11 days to induce diabetes, then, on day 12, the animals
were segregated into two subgroups: (a) TAC-day-12 (Refer-
ence Group), formed by 22 animals which were subjected to an
intraperitoneal glucose tolerance test (IPGTT), and were then
sacriﬁced; and (b) TAC-CsA: formed by 22 animals, wherein
TAC was replaced with CsA on day 12 of treatment, for 5 days;
on day 17, the animals underwent IPGTT and were then sacri-
ﬁced. The control group consisted of 45 animals that received
the vehicle (PBS) for 12 days; IPGTT was performed on 23
of them, and they were sacriﬁced on day 12. Twenty-two of
them received an IPGTT on day 17, and were then sacriﬁced
(Fig. 1).
In our prior study,11 all the animals presented diabeteswith
severely high blood sugar after 12 days with TAC, which was
reversed with the removal of the drug. Additionally, some ani-
mals died during the IPGTT on day 1211 due to severely high
blood sugar. In this way, for this study, we considered that
animals treated with TAC for 12 days already had established
diabetes and, therefore, we did not extend the treatment with
TAC to 17 days. To determine the length of treatment with
CsA after the change (TAC-CsA), we carried out preliminary
analyses in a subgroup of animals (n=5) with daily measure-
ments of glucose levels while fasting after the change to CsA.
All the animals showednormal glucose values (<126mg/dL) on
the ﬁfth day after the change to CsA, therefore, so we there-
fore decided to run the drug conversion study for ﬁve days
after making the change to CsA.12, or received PBS for 17 days (PBS, n=22).
The animals treated with TAC got a daily intraperi-
toneal injection of TAC (0.3mg/kg/day), and those who were
changed to CsA received 2.5mg/kg/day. The dosages of TAC
(0.3mg/kg/day) andCsA (2.5mg/kg/day) usedweredetermined
in prior experiments11 to obtain plasma levels similar to those
used in clinical practice, both for CsA (200–250ng/mL) and for
TAC (8–10ng/mL).
The animals were weighed daily, and their glucose lev-
els while fasting were measured on days 12, 14 and 17.
On day 12 of the group TAC-d12 (n=20) and on day 17 of
the group TAC-CsA (n=15), underwent IPGTT with glucose
(2 g/kg), and glucose and insulin levels were measured at 0,
30, 60, and 120min. The animals with PBS also underwent
IPGTT on days 12 and 17. All the animals were sacriﬁced
with an intraperitoneal injection of pentobarbital sodium
(50mg/kg).
On day 12, for groups PBS and TAC-d12, as well as on day
17 for PBS and TAC-CsA, the pancreas of 10 animals per group
was removed for immunohistochemical and morphometrical
analysis. The pancreas of another 10 animals of each group
was removed for analysis of insulin gene expression.
Serum samples collected from the abdominal aorta were
obtained to measure the levels of insulin and the biochemi-
cal parameters. The biochemical determinations were carried
out in the central laboratory of the Hospital Universitario de
Canarias.
Deﬁnitions
Diabetes: blood sugar level while fasting ≥126mg/dL or
>200mg/dL after 120min from the IPGTT (9). Pre-diabetes:
abnormal blood sugar levels while fasting (ABSF): fas-
ting glucose ≥100–125mg/dL or glucose intolerance (GIT):
≥140–199mg/dL 120min after IPGTT.9
Morphometrical and immunohistochemical analysis
On day 17, among 10 OZR per treatment group, the pancreas
was removed and placed for 24h in 4% paraformaldehyde,
and later included in parafﬁn. Serial 3m-thick sections were
made and placed on slides. For morphometrical analysis, the
pancreas were stained with anti-insulin serum of guinea pig
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nd revealed with immunologic methods based on biotin-
treptavidin. The number of islets and the relative surface
f the same based on the total surface of the pancreas were
etermined.
-Cell proliferation was measured using the bromod-
oxyuridine (BrdU) addition method (Roche, Switzerland). The
nimals were injected with BrdU (100mg/kg) 8h before being
acriﬁced. The pancreas was removed and processed as pre-
iously mentioned. The histologic sections were stained with
ntibodies for BrdU and insulin. Proliferation was measured
s an estimate of the number of BrdU-positive cells based on
he number of positive cells for insulin. The levels of apopto-
is were measured with the TUNEL technique, and the same
as carried out according to manufacturer speciﬁcations (Cell
eath detection kit, POD) (Roche-Switzerland). The estimate
f positive cells in TUNEL was adjusted to the positive surface
or insulin. All the images were taken using an Olympus DP72
amera (Olympus, Tokyo-Japan) coupled to an Olympus DX41
icroscope (Olympus, Tokyo, Japan), and later analysed using
oftware ImageJ software (National Institute of Health).
NA extraction
he islets of the remaining animals (n=10 per treatment)
ere isolated from the pancreas by means of digestion with
ollagenase.17 The islets used for RNA isolation were quickly
rozen in D solution with thiocyanate guanidine. The total
NA was obtained with Chomczynski’s method.18 We deter-
ined the purity and concentration of RNA with Nano-drop
000 (Thermo-Fisher, Boston, MA).
eal-time PCR
he quantitation of relative abundance of mRNA of Ins2
as carried out by means of quantitative CRP (qCRP) using
YBR green as the detection method. The total RNA of the
ample was retro-transcribed using a cDNA synthesis kit
Promega, Madison, WI) and the cDNA of Ins2 was ampliﬁed
sing speciﬁc primers. The sequence of oligonucleotides used
as the following: 5′-TCATCCTCTGGGAGCCCCGC-3′ (sense
rimer); and 5′-GTTGCAGTAGTTCTCCAGTTGGT-3′ (anti-sense
rimer). The ﬂuorescence increase during the CRP reaction
as detected with the iQ5 system (Bio-Rad. Hercules, CA), and
he gene expression was normalised with the reference genes
eta-actin and SDHA. The data was analysed with qBASE
oftware.19
tatistical analysis
he continuous variables are described as mean and standard
eviation (SD) or mean and interquartile range when appro-
riate, while the dichotomous variables are represented with
and %. The groups were compared using a non-parameter
ruskal–Wallis test and the Mann–Whitney test, as necessary.
or the qPCRdata,we carried out a logarithmic transformation
f the normalised gene expression, giving more symmetry to
istribution, attributing equalweight to higher and lower gene
xpression conditions.20(3):264–272 267
Results
Homeostasis of glucose after 11 days with Tacrolimus
According to blood sugar levels while fasting, TAC induced
diabetes in 100% of the animals by day 12 (Fig. 2). No ani-
mal with PBS developed diabetes, and only 26.7% (12/45) had
pre-diabetes (Fig. 2). On day 12, 95% of the animals with
TAC, which underwent IPGTT (n=20), presented glucose lev-
els >200mg/dL after 120min (Fig. 2). Only one animal had
blood sugar levels between 140 and 200mg/dL. No animal
with PBS presented diabetes based on the IPGTT on day 12
(Fig. 2).
Homeostasis of glucose after the change from Tacrolimus
to Cyclosporine
Between days 12 and 17, after changing from TAC to CsA, fas-
ting glucose levels decreased in the TAC-CsA group (Fig. 3a),
and glucose levels on day 17 were signiﬁcantly lower than
compared to those of day 12 (p<0.001) (Fig. 3a). Based on fas-
ting blood sugar levels, in the group TAC-CsA only one of
22 animals persisted with diabetes (4.5%), 13 of 22 (59.1%)
had pre-diabetes, and 9 of 22 (36.4%) showed normal blood
sugar while fasting (Fig. 2). Based on the IPGTT, 7 of 15 (46.7%)
animals maintained diabetic values (2-h glucose >200mg/dL)
in the group TAC-CsA, and 8 of 15 (53.3%) presented normal
blood sugar (<140ml/dL) on day 17 (Fig. 2). At each point of the
IPGTT, the animals of the TAC-CsA group presented higher
blood sugar levels than those of the PBS group (Fig. 3b) but
lower levels than those in the TAC-d12 group (Fig. 3b). Finally,
on day 17, the animals with PBS presented normal IPGTT
(Fig. 3b).
During the IPGTT of day 17, the animals that had been
changed fromTAC to CsA did not show an increase in the early
secretion of insulin (0–30min), but they did show lower insulin
levels than the group with PBS (Fig. 3c), being comparable
to the levels measured in the group TAC-d12 (Fig. 3c). How-
ever, during a sensitivity analysis, insulin secretion improved
in the animal subgroup where diabetes was reversed after
the change to CsA (n=8), as shown by a tendency towards
higher levels of insulin after 30 and 60min, and signiﬁ-
cantly higher levels after 120min, compared with the animals
where diabetes persisted in spite of the change to CsA (n=7)
(Fig. 3d).
Finally, on day 12, TAC levels in the TAC-d12 were
8.37±3.94ng/mL; on day 17, the CsA levels in the TAC-CsA
group were 508.18±67.85ng/mL, with residual levels of TAC
of 2.46±0.90ng/mL.
Proliferation of beta pancreatic cells, apoptosis and gene
expression of insulin after 11 days with Tacrolimus
and after the change to Cyclosporine
Quantitation of positive cells for insulin with bromodeoxyuri-
dine showed a lower proliferation in TAC-d12 after 11 days
of treatment than in the group with PBS (p=0.009) (Fig. 4a).
When comparing the change from TAC to CsA (TAC-CsA) with
the TAC-d12 group, the proliferation rate of  cells improved
268 nefrolog ia. 2015;35(3):264–272
Fig. 2 – Percentage of obese Zucker rats with diabetes, pre-diabetes or without alterations in the glucose metabolism,
according to the blood sugar levels while fasting (left), or with an intraperitoneal glucose tolerance test (IPGTT) (right)
on days 12 and 17.signiﬁcantly (p=0.003) (Fig. 4a). No differences in apoptosis
were observed between the two groups (Fig. 4b).
The relative islet surface was also lower in the TAC-d12
group when compared to the PBS group (p=0.011) (Fig. 5) but
there were no differences with TAC-CsA. No differences were
noted in the relative number of islets for either of the groups.
Eleven days with Tacrolimus (TAC-d12) signiﬁcantly
reduced the expression of the Ins2 gene compared to the group
with PBS (p≤0.0001) (Fig. 6). Five days after the change to CsA
(TAC-CsA), Ins2 gene expression returned to values compara-
ble to those of PBS (p=0.755) and it was signiﬁcantly increased
versus TAC-d12 (p≤0.0001) (Fig. 6).
Discussion
In this model of diabetes induced by tacrolimus in animals
with resistance to insulin,wehave observed that the change to
Cyclosporine-A leads to: (1) improved blood sugar levels, both
fasting and during IPGTT; (2) a reversion of diabetes in 53.3%
of the animals; (3) an improvement in -cell proliferation; and,
ﬁnally, (4) an increase in insulin gene expression.
The obese Zucker rat (OZR) is a known model of insulin
resistance. We have previously observed that in OZR, the
greatest diabetogenic effect of TAC compared to CsA is deter-
mined by insulin resistance.11 For this study, the objective of
which was to better understand the reversion mechanisms
of NODAT, we used OZR instead of insulin-sensitive model
animals such as Sprague Dawley, Wistar, or TZR. We have
conﬁrmed our prior ﬁndings, wherein the administration ofTAC during 11 days induced diabetes in 100% of the insulin-
resistant animals, diagnosed either by blood sugar levelswhile
fasting or by IPGTT (Figs. 2 and 3).
Our main ﬁnding is that in diabetes induced by TAC, the
change to CsA leads to an improvement in the metabolism
of glucose and to a reversibility of diabetes in 50% of the ani-
mals (Fig. 2). This reversibility was noted only 5 days after the
change to CsA (Fig. 3a and b). However, it was not complete,
since 59.1% of the animals showed blood sugar levels within
the pre-diabetes range (due to baseline blood sugar while fas-
ting), and in 46.7% the diabetes persisted according to the
IPGTT results (blood sugar after 120min >200mg/dL) (Fig. 2). In
thisway, the changes tohomeostasis of glucose, although rele-
vant if compared to the diabetes established in the group TAC,
did not represent a total reversibility of the diabetes induced
by the drug.
The causes for glucosemetabolism improvement after sub-
stituting TAC for CsA are not clear, but they could be in part
related to an increase in the proliferation of  cell (Fig. 4). We
have previously observed that TAC is a stronger inhibitor of 
cell proliferation than CsA.11 With this, it is plausible that the
substitution of a strong proliferation inhibitor (TAC) for a less
stronger one (CsA) will help the  cell to recover, to a certain
extent, its proliferative capability, and, as a consequence, to
better manage the high blood sugar levels. Currently,  cells
are considered more resistant to damage than was previously
believed, with high recovery capability in the face of a toxic
environment.21 In our study, a reduction in the mean sur-
face of pancreatic islets after 11 days of treatment with TAC
is particularly remarkable, which does not correspond to an
nefrolog ia. 2015;35(3):264–272 269
Fig. 3 – Progress of blood sugar levels and levels of insulin of OZR. (a) Blood sugar while fasting for PBS (grey line) and TAC
(black line), (b) blood sugar levels, and (c) levels of insulin in the IPGTT on day 17. The grey line corresponds to PBS, and the
black line to TAC-CsA. Black, discontinuous line TAC-d12, (d) levels of insulin in the IPGTT on day 17, for the animals of the
group TAC-CsA with reversion of diabetes (grey line) or persistent diabetes (discontinuous line). (a) *: TAC-CsA vs PBS
p≤0.0001. (b) a: all the comparisons p=0.0001; b: TAC-CsA or TAC-d12 vs PBS p=0.0001, TAC-CsA vs TAC-d12 p=0.005; c:
TAC-CsA and TAC-d12 vs PBS p=0.0001; TAC-CsA vs TAC-d12 p=0.0001; d: TAC-CsA vs PBS p=0.012, TAC-d12 vs PBS
p=0.0001, TAC-d12 vs TAC-CsA. p=0.002. (c) e: TAC-CsA or TAC-d12 vs PBS p>0.05, TAC-d12 vs TAC-CsA p=0.031, f:
TAC-CsA vs PBS and vs TAC-CsA p>0.05, TAC-d12 vs PBS p=0.033; g: TAC-CsA vs PBS p=0.042, TAC-d12 vs PBS p=0.002,
TAC-d12 vs TAC-CsA p=0.011; h: TAC-CsA and TAC-d12 vs PBS p≤0.0001, TAC-d12 vs TAC-CsA. p=0.002. (d)
TAC-CsA-reversion of diabetes vs TAC-CsA-persistence of diabetes i, j and k: p>0.05, l: p=0.005.
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tquivalent increase in the apoptosis of beta cell. In this regard,
umerous efforts have been made to determine the mecha-
isms causing a decrease in the function and in the number of
eta cells among patients with DMT2. New evidence suggests
hat these changes could be due to de-differentiation or trans-
ifferentiation processes in the cells, and not to apoptosis
rocesses, which suggests a new concept in the pathogene-
is of beta cell dysfunction.22 These new hypotheses would be
n agreement with our model, wherein a loss of the identity
arker of a beta cell such as insulin is observed, but, on
he contrary, no apoptosis increase is noted. Additionally, the
uick recovery observed after the drug change, as well as
he previously observed quick withdrawal,11 supports the
otion of a loss of function and identity of the beta cell rather
han a process of cellular death. In any event, future experi-
ents are required to conﬁrm these hypotheses for thismodel
f diabetes induced by inhibitors of calcineurin.
We have also noted in prior studies that TAC is a stronger
nhibitor of the gene Ins2 expression than CsA.11 According
o these data, the expression of gene Ins2 (homologous to thehuman proinsulin gene) after being exposed to TAC (TAC-d12)
for 11 days was signiﬁcantly lower than in animals who only
received the vehicle (PBS) for 17 days (Fig. 6). The increase in
the expression of gene Ins2 after the change to CsA was sig-
niﬁcantly higher when compared to the group that was only
administered TAC (p≤0.0001 vs TAC-d12), which suggests that
an improvement in the expression of the gene Ins2 could be
related to better management of glucose after the change to
CsA.
Themolecularmechanisms involved in the increase of pro-
liferation of  cell associated with the change of TAC to CsA
are, to the best of our knowledge, unknown. The fact that TAC
is a stronger inhibitor of calcineurin than CsA23 could explain
the greater impact of the ﬁrst on the decrease of calcineurin-
dependent transcription factors such as the nuclear factor of
T cells (NFAT), the element of response to cAMP (CREB), and
the CREB transducer (TORC2), which are crucial for the prolif-
eration of  cell.24–26
Our results are consistent with the few retrospective stud-
ies carried out on humans.10 Ghisdal et al. observed 42%
270 nefrolog ia. 2015;35(3):264–272
Fig. 4 – Proliferation (a) and apoptosis (b) of beta cells. The mean is represented±SD. (a) a: TAC-d12 vs PBS p=0.009; b:
TAC-CsA vs PBS p=0.001 and vs TAC-d12 p=0.003. (b) c: TAC-d12 v PBS p=0.172. d: TAC-CsA vs PBS p=0.311 and vs
TAC-d12 p=0.824.
of reversibility of PTDM with the change of TAC to CsA in
34 patients, and 0% in 20 patients who continued with TAC.10
In said work, the authors also quoted another clinical study
with similar ﬁndings. However, theseworks present a post hoc
design, and low statistical strength to prove efﬁcacy and secu-
rity. This work on animals with insulin resistance provides
information on the mechanisms and the way in which the
Fig. 5 – Morphometry of the OZR islets treated with PBS or TAC fo
(TAC-CsA) for 5 days (n=10 per treatment). (a) Surface of islets ad
adjusted to mm2 of pancreas. The mean is represented±SD. (a)
vs TAC-d12 p=0.197. (b) c: TAC-d12 vs PBS p=0.523. d: TAC-CsAimprovement of glucose metabolism is associated to an early
change to CsA, once the diabetes induced by TAC is estab-
lished. Future clinical trials will be required to establish the
role that this strategy could have at the time of minimising
damage caused to the  cell while establishing the PTDM.
Our study has limitations. The ﬁrst is the application
of data obtained in an animal model to clinical research.
r 11 days (TAC-d12), or TAC for 11 days with change to CsA
justed to the total surface of pancreas. (b) Number of islets
a: TAC-d12 vs PBS p=0.011. b: TAC-CsA vs PBS p=0.016 and
vs PBS p=0.078 and vs TAC-d12 p=0.892.
nefrolog ia. 2015;35
Fig. 6 – Expression of the gene Ins2 in OZR with PBS or TAC
for 11 days (TAC-d12) or TAC for 11 days with change to
CsA (TAC-CsA) for 5 days (n=10 per treatment). The mean
is represented±SD. a: TAC-d12 vs PBS p≤0.0001; b:
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tolerance test in genetically obese (fa/fa) rats. Am J PhysiolAC-CsA vs PBS p=0.755 and vs TAC-d12 p≤0.0001.
owever, the coincidences between this work and retrospec-
iveworks publishedonhumans10 couldhint at theusefulness
f this animal model for the study of the impact of changing
rom TAC to CsA on the metabolism of glucose and on the
iology of the  cell. The second limitation is with regards to
he application of human criteria such as pre-diabetes and
iabetes to an animal model. However, this is a standard in
asic research,26–29 and, to the best of our knowledge, there is
o clear consensus for these deﬁnitions on rodents. Another
imitation is related to the length of the change; 5 days of
hange to CsA could be too few, but during those days, the
lucose levels while fasting showed signiﬁcant improvements
y day 17. Further, our results show that it is sufﬁcient time
o dilute the toxic effect of TAC, and, therefore, to rule out the
ossibility of an accumulative effect of bothdrugs on the cell.
he effect which could occur on the homeostasis of glucose
ollowing a longer exposure to CsA should be established in
he future. In this study, we used relatively high levels of CsA,
hich couldhave increased the risk of diabetes in animals that
eceived this drug. However, the use of lower levels could only
ave increased the differences with the group of tacrolimus.
astly, in this animal model, the diabetes was established
fter a short period of exposure to the drug, and the experi-
ent was not designed to assess the reversibility of diabetes
fter a long period of time, which should be researched.
In summary, we can conclude that in diabetes induced by
acrolimus, the change to Cyclosporine improves the homeo-
tasis of glucose, which is related to an increase in the
roliferation of  cell and possibly to an increase in the expres-
ion of the insulin gene. The ad-hoc assessment of this effect
n patients with PTDM should be studied.
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